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1. Introduction
Butyrylcholinesterase (EC 3.1.1.8; BChE) also known as
pseudocholinesterase and serum cholinesterase, is the sister
enzyme of acetylcholinesterase (EC 3.1.1.7; AChE). It is present
in most tissues including human plasma where its concentration is
about 50 nM (4.2 mg per liter). Though BChE lacks obvious
physiological functions, it is of toxicological and pharmacological
importance in detoxifying or catabolising ester-containing drugs [1].
Furthermore, individuals deﬁcient in BChE appear asymptomatic,
apart from a heightened sensitivity to the muscle relaxants
suxamethonium and mivacurium, two BChE carboxylester substrates
used as myorelaxant [2]. In patients with usual BChE levels, these
drugs are rapidly hydrolyzed in plasma and their duration of action is
short (<10 min). BChE deﬁciency results in slower hydrolysis of these
drugs and, consequently, a prolonged neuromuscular block, leading
to apnea. Prolonged neuromuscular block occurs with BChE
deﬁciencies of marked severity (impairment >70%). Although many
acquired conditions may affect BChE activity (liver or renal diseases,
malnutrition, pregnancy, malignancy), BChE deﬁciency is mainly due
to mutations in the BCHE gene (MIM 177400) [2].
Prolonged apnea following injection of succinylcholine was ﬁrst
described in 1953 [3]. The genetics of BChE deﬁciency was
described by Kalow and Genest in 1957 and is said to be a
cornerstone in pharmacogenetics/pharmacogenomics [4]. The
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A B S T R A C T
Butyrylcholinesterase deﬁciency is characterized by prolonged apnea after the use of muscle relaxants
(suxamethonium or mivarcurium) in patients who have mutations in the BCHE gene. Here, we report a
case of prolonged neuromuscular block after administration of mivacurium leading to the discovery of a
novel BCHE variant (c.185C>T, p.Ala34Val). Inhibition studies, kinetic analysis and molecular dynamics
were undertaken to understand how this mutation remote from the active center determines the ‘‘silent’’
phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and
benzoylcholine, and values of dibucaine and ﬂuoride numbers ﬁt with a heterozygous enzyme of type
atypical/silent. Kinetic analysis with succinyldithiocholine (SCdTC) as the substrate showed that
Ala34Val BChE was inactive against this substrate. However, with BTC, the mutant enzyme was active,
displaying an unexpected activation by excess substrate. Competitive inhibition of BTC by mivacurium
gave a Ki = 1.35 mM consistent with the lack of activity with the related substrate SCdTC, and with the
clinical data. Molecular dynamic simulations revealed the mechanism by which mutation Ala34Val
determines the silent phenotype: a chain of intramolecular events leads to disruption of the catalytic
triad, so that His438 no longer interacts with Ser198, but instead forms hydrogen bonds either with
residues Glu197 and Trp82, or peripheral site residue Tyr332. However, at high BTC concentration, initial
binding of substrate to the peripheral site triggers restoration of a functional catalytic triad, and activity
with BTC.
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